

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

PROFIT WARNING ALERT

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2015 (the “**Management Accounts**”), the Group expects to record an operating loss in the current period in spite of having improvement in performance of the Group’s trading and manufacturing segments, as compared to a profit for the corresponding period in 2014.

The loss in the current period was primarily attributable to non-cash items including a decrease in fair value of derivative component of the Group’s investments in convertible bonds of approximately HK\$63 million and partially offset by its effective interest income of approximately HK\$31 million. During the same period in 2014, there was a gain on disposal of the Group’s 51% equity interest in Smart Ascent Limited in July 2014 of about HK\$304 million (restated as about HK\$612 million in the audited consolidated financial statements for the year ended 31 March 2015) which was one-off in nature.

The Company is still in the process of preparing the interim results of the Group for the six months ended 30 September 2015, the information as set out above is only based on the preliminary assessment by the Board on the information currently available to it, including the Management Accounts, which have yet to be confirmed. The unaudited consolidated interim results of the Group for the six months ended 30 September 2015 are expected to be announced by the Company before the end of November 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Chairman

Hong Kong, 13 November 2015

As at the date of this announcement, the executive directors are Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

** For identification purpose only*